Moderna and Merck's Cancer Vaccine Breakthrough Sparks Market Uptick

Pharmaceutical giants Moderna and Merck have reported promising results from an experimental vaccine treatment that may prevent cancer recurrence in high-risk melanoma patients. The mRNA-based vaccine, called Intismeran, was tested in a late-stage trial involving individuals who had already undergone surgery to remove a melanoma tumor.

The study used the personalized cancer vaccine in combination with Merck's cancer immunotherapy Keytruda. According to interim results from the trial, the vaccine-drug combo appeared to extend the time before cancer returned in high-risk patients.

Moderna's CEO, Stéphane Bancel, described the findings as a 'pivotal moment for the field of cancer research.' The companies will continue to examine overall survival rates following the treatment and plan to present their results at an upcoming medical meeting and share them with regulators.

The news sent Moderna shares soaring by up to 106% in pre-market trading, while Merck's shares rose by 7%. This breakthrough has significant implications for cancer research, as it represents a potential new approach to preventing cancer recurrence.